Incidence and impact of de Novo donor-specific alloantibody in primary renal allografts

Transplantation

Volumn 95, Issue 3, 2013, Pages 410-417

  Everly, Matthew J ^a   Rebellato, Lorita M ^b   Haisch, Carl E ^b   Ozawa, Miyuki ^c   Parker, Karen ^b   Briley, Kimberly P ^b   Catrou, Paul G ^b   Bolin, Paul ^b   Kendrick, William T ^d   Kendrick, Scott A ^d   Harland, Robert C ^b   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c One Lambda Inc   (United States)

^d Eastern Nephrology Associates   (United States)

Author keywords

Allograft survival; Donor specific antibodies; Epidemiology; Human leukocyte antigen

Indexed keywords

ALLOANTIBODY; DE NOVO DONOR SPECIFIC ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; CHRONIC ALLOANTIBODY MEDIATED REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC ALLOGRAFT VASCULOPATHY; CHRONIC GRAFT REJECTION; COHORT ANALYSIS; DONOR; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INCIDENCE; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84873377509     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827d62e3     Document Type: Article

References (30)

1. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103.
2. Kimball PM, Baker MA, Wagner MB, et al. Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011; 79: 1131.
3. Mohanakumar T, Giedlin MA, Rhodes CL Jr, et al. Relationship of B cell alloantibodies to renal allograft survival. Transplantation 1979; 27: 273.
4. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
5. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408.
6. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
7. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
8. Devos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598.
9. Martin S, Dyer PA, Mallick NP, et al. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50.
10. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86: 377.
11. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
12. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008; 8: 1662.
13. Bentall A, Gloor J, Cornell LD, et al. Five year outcomes of positive crossmatch kidney transplants: insight into late graft injury. Am J Transplant 2012; 12: 227.
14. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
15. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29: 973.
16. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
17. Lee PC, Zhu L, Terasaki PI, et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
18. Mizutani K, Terasaki PI. Serum creatinine levels in 10-year survivors of cadaveric kidney transplants. Clin Transpl 2003: 441.
19. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312.
20. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
21. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80: 1194.
22. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
23. Zarkhin V, Kambham N, Li L, et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008; 74: 664.
24. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
25. Everly MJ, Rebellato LM, Ozawa M. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection (vol 89, pg 962, 2010). Transplantation 2010; 90: 103.
26. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
27. Zhou YC, Cecka JM, Terasaki PI. Effect of race on kidney transplants. Clin Transpl 1990: 447.
28. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
29. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteriaVan addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
30. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.